Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament composition

A composition and drug technology, applied in the field of medicine, can solve the problems of low oral bioavailability, insoluble in water, etc.

Inactive Publication Date: 2009-01-14
陈亚玲 +1
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] The current milk thistle extract preparation has the following disadvantages in clinical use: insoluble in water, low oral bioavailability
[0022] The common feature of the above patents is that they contain only milk thistle extract - a single active therapeutic ingredient of silybin, silymarin or its derivatives

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0052] The present invention also provides a preparation method of the pharmaceutical composition, which comprises, based on the weight of the final pharmaceutical composition, adding 0.01-30% by weight of all or part of phospholipids, and 0.001-30% by weight of milk thistle The extract is dissolved in 0.001-30% by weight of natural volatile oil to make it fully dissolved. If the amount of natural volatile oil cannot meet the needs of preparation preparation, an appropriate amount of other pharmaceutically acceptable vegetable oils can be added thereto to obtain oil Phase steps.

[0053] In the method of the present invention, the method for dissolving phospholipids in pharmaceutically acceptable natural volatile oil and optionally other vegetable oils is not particularly limited. The oil phase may be formed using any mixing method known in the art.

[0054] The method of the present invention also includes adding the remaining amount of phospholipids and an isotonic regulato...

Embodiment 1

[0065] Milk of the pharmaceutical composition is prepared.

[0066] (1) Pharmaceutical composition The distribution ratio of each component of milk is shown in Table 1 (made into 1000ml).

[0067] Table 1

[0068] component name

weight ratio(%)

Feed amount (g)

effect

Curcuma Oil

1.0

10.0

Main drug

Silymarin

0.5

5.0

Main drug

Soybean oil

9.0

90.0

solvent

egg yolk lecithin

1.2

12.0

drug carrier, emulsifier

Glycerol

2.25

22.5

isotonicity regulator

Water for Injection

86.05

860.5

solvent

[0069] (2) Preparation of pharmaceutical composition milk

[0070] a. dissolve the egg yolk lecithin of the prescribed amount in the zedoary oil, then add silymarin to it to make it fully dissolved, and then slowly add soybean oil; obtain the oil phase liquid;

[0071] b. Add glycerol to water for injection, stir evenly; obtai...

Embodiment 2

[0077] Milk of the pharmaceutical composition is prepared.

[0078] (1) Pharmaceutical composition The distribution ratio of each component of milk is shown in Table 1 (made into 1000ml).

[0079] Table 2

[0080] component name

weight ratio(%)

Feed amount (g)

effect

safflower oil

0.001

0.01

Main drug

Silybin

0.001

0.01

Main drug

Soybean oil

9.999

99.99

solvent

Soy lecithin

1.2

12.0

drug carrier, emulsifier

[0081] Glycerol

2.25

22.5

isotonicity regulator

Water for Injection

86.549

865.49

solvent

[0082] (2) Preparation of pharmaceutical composition milk

[0083] a. dissolving the soybean lecithin of the prescribed amount in safflower oil, then adding silibinin to it to make it fully dissolved, then slowly adding soybean oil; obtaining an oil phase liquid;

[0084] b. Add glycerol to water for i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug composite. The drug composite based on the final weight of the drug composite comprises 0.001 to 30 weight percentage of milk thistle extract as a first essential component, 0.001 to 30 weight percentage of natural volatile oil acceptable to pharmacy as a second essential component, 0.01 to 30 weight percentage of phospholipids as a third essential component; moderate isoosmotic adjustment agent acceptable to the pharmacy, stabilizing agent, optional vegetable oil acceptable to the pharmacy and water. The invention also discloses a preparation method of the drug composite.

Description

technical field [0001] The invention belongs to the technical field of medicine, and the essential components relate to medicine-silymarin extract; pharmaceutically acceptable natural volatile oil. It comprises by weight of the final pharmaceutical composition: 0.001-30% by weight of milk thistle extract as the first essential component; 0.001-30% by weight of pharmaceutically acceptable natural volatile oil as the second essential component ; 0.01-30% by weight of phospholipid as the third essential component; and appropriate amount of pharmaceutically acceptable isotonic regulator, stabilizer, pharmaceutically acceptable vegetable oil and water. The invention also discloses its preparation method. Background technique [0002] Milk thistle extract is the main active ingredient isolated from the seeds of milk thistle, a plant in the family Asteraceae. It includes silybin, silymarin or silymarin derivatives (silymarin, silymarin and isosilymarin). Experiments have shown t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/357A61K9/107A61K9/127A61P1/16
Inventor 陈亚玲傅磊
Owner 陈亚玲
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com